Ask AI
ProCE Banner Activity

Expert Insights Into Testing and Targeted Therapy for Early-Stage NSCLC

Clinical Thought

In this commentary, expert oncologists and pathologists discuss key considerations for molecular testing and treatment for early-stage NSCLC, including establishing workflows for essential tests, current and emerging targeted therapy strategies, and more.

Released: June 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for global medical oncologists, thoracic oncologists, pulmonologists, thoracic surgeons, pathologists, molecular biologists, and other healthcare professionals who care for patients with early-stage NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate colleagues on the rationale and clinical utility of comprehensive molecular testing in early-stage NSCLC

  • Perform molecular testing in each patient with early-stage NSCLC consistent with current evidence and local expert guidance

  • Develop processes to optimize interdisciplinary communication and collaboration to ensure timely and accurate interpretation of molecular testing for each patient with early-stage NSCLC

  • Recommend the optimal targeted therapy or immunotherapy for each patient with early-stage NSCLC, considering molecular testing results, patient/disease factors, evidence, and local expert guidance

  • Appraise emerging evidence and ongoing clinical trials of novel targeted therapies and immunotherapies and the clinical implications for management of early-stage NSCLC

Financial Disclosures

Primary Author

Jamie E. Chaft, MD: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, EMD Serono, Exact Sciences, Genentech/Roche, Guardant, Foundation Medicine, Natera, Nuvation Bio, Revolution; researcher (paid to institution): AstraZeneca, BioNtech, Boehringer Ingelheim, Bristol Myers Squibb, Genentech/Roche, Lilly, Merck, Taiho.

Fernando Lopez-Rios, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Lilly, MSD, Pfizer, Regeneron; researcher: AstraZeneca, Janssen, Lilly, Pfizer, Roche, Thermo Fisher.

Luis Paz-Ares, MD, PhD: honoraria: Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Jazz, Lilly, Merck Serono, Mirati, Novartis, Pfizer, PharmaMar, Roche/Genentech, Sanofi, Takeda; founder and board member: ALTUM Sequencing, Stab Therapeutics; research funding (to Institution): AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, PharmaMar; speaker: Bristol Myers Squibb, Lilly, Merck Serono, Merck Sharp & Dohme, Pfizer, Roche/Genentech.

Soo Ryum (Stewart) Yang, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Lilly, Merus, Revolution Medicines, Roche, Sanofi.